Gilead Sciences, Inc. vs Monolithic Power Systems Inc — how do they compare? Gilead Sciences, Inc. trades at $135.49 (market cap $168.35B), while Monolithic Power Systems Inc trades at $1,430 (market cap $68.90B). The key difference: Gilead Sciences, Inc. is far larger — about 2.4× Monolithic Power Systems Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | MPWR | |
|---|---|---|
Market Cap | $168.35B | $68.90B |
Sector | Health | Utilities |
52-Week High | $155.80 | $1.69K |
52-Week Low | $110.56 | $820.74 |
Enterprise Value | $191.42B | $67.51B |
Dividend Yield | 2.42% | 0.57% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →